A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

Summary

The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual disease (MRD-negative, meaning there are no detectable cancer cells). Participants in this study will have received past treatment for their B-cell ALL, and their disease will be in MRD-negative CR for the first time (first MRD-negative CR).

Timeline

Start

2026-02-03

Primary completion

2029-02

Completion

2029-02

Drugs

Indications